Lactobacillus and bifidobacteria combinations: A strategy to reduce hospital-acquired Clostridium difficile diarrhea incidence and mortality

Medical Hypotheses

Volumn 73, Issue 2, 2009, Pages 194-198

  Graul, Terry ^a   Cain, Alisha M ^b   Karpa, Kelly D ^c  

^a Clin Path Associates   (United States)

^b WILKES UNIVERSITY   (United States)

^c An Apple A Day Health Solutions LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; FLORAJEN 3; PLACEBO; PROBIOTIC AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BIFIDOBACTERIUM; BIFIDOBACTERIUM BIFIDUM; CLINICAL TRIAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG CAPSULE; DRUG EFFICACY; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITAL PATIENT; HUMAN; INCIDENCE; INTESTINE; INTESTINE FLORA; LACTOBACILLUS; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS RHAMNOSUS; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; OPPORTUNISTIC INFECTION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RISK REDUCTION;

BIFIDOBACTERIUM; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DIARRHEA; HUMANS; INCIDENCE; LACTOBACILLUS;

CLOSTRIDIUM DIFFICILE; LACTOBACILLUS;

EID: 67349169055     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2009.02.026     Document Type: Article

References (46)

1. Karpa KD. A gut wrenching experience: probiotics and diarrhea. In: Bacteria for breakfast: probiotics for good health. Victoria, BC, Canada: Trafford; 2003. p. 104-43.
2. Seki H., Shiohara M., Matsumura R., et al. Prevention of antibiotic-associated diarrhea in children by Clostridium buyricum MIYARI. Ped Internat 45 (2003) 86-90
3. Imase K., Takahashi M., Tanaka A., et al. Efficacy of Clostridium butyricum preparation concomitantly with Helicobacter pylori eradication therapy in relation to changes in the intestinal microbiota. Microbiol Immunol 52 (2008) 156-161
4. Sunenshine R.H., and McDonald L.C. Clostridium difficile-associated disease: new challenges from an established pathogen. Cleve Clin J Med 73 2 (2006) 187-197
5. Bergogne-Berezin E. Treatment and prevention of antibiotic associated diarrhea. Int J Antimicrob Agents 16 4 (2000) 521-526
6. Pepin J., Saheb N., Coulombe M.-A., et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41 9 (2005) 1254-1260
7. Gaynes R., Rimland D., Killum E., et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis 38 5 (2004) 640-645
8. Loo V.G., Poirier L., Miller M.A., et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 353 23 (2005) 2442-2449
9. O'Marra N.B. Severe infections caused by Clostridium difficile - a growing problem. Pharmacist Lett 22 (2006) 220108
10. Bartlett J.G. Narrative review: the new epidemic of Clostridium difficile-associated enteric disease. Ann Intern Med 145 10 (2006) 758-764
11. Warny M., Pepin J., Fang A., et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 366 9491 (2005) 1079-1084
12. Woelfel J.A. Proton pump inhibitors associated with increased risk of Clostridium difficile diarrhea. Pharmacist Lett 20 (2004) 200804
13. Musher D.M., Aslam S., Logan N., et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 40 11 (2005) 1586-1590
14. McFarland L.V., Surawicz C.M., Rubin M., Elmer G.W., and Greenburg R.N. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 20 1 (1999) 43-50
15. Surawicz C.M., McFarland L.V., Greenberg R.N., et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 31 4 (2000) 1012-1017
16. Wysowski D.K. Surveillance of prescription-related mortality using death certificate data. Drug Saf 30 6 (2007) 533-540
17. Pennsylvania Health Care Cost Containment Council. Clostridium difficile infection in Pennsylvania hospitals. Issue 11; May 2007. Available from: www.phc4.org/reports/researchbriefs/051107/docs/researchbrief051107.pdf [accessed 12.02.09].
18. McFarland L.V., Beneda H.W., Clarride J.E., and Raugi G.J. Implications of the changing face of Clostridium difficile disease for health care practitioners. Am J Infect Control 35 4 (2007) 237-253
19. Miller M.A., Hyland M., Ofner-Agostini M., Gourdeau M., and Ishak M. Canadian Hospital Epidemiology Committee. Canadian Nosocomial Infection Surveillance Program. Morbidity, mortality, and healthcare burden of nosocomial Clostridium difficile-associated diarrhea in Canadian hospitals. Infect Control Hosp Epidemiol 23 3 (2002) 137-140
20. Kyne L., Hamel M.B., Polavaram R., and Kelly C.P. Healthcare costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34 3 (2002) 346-353
21. McCoppin R. Hospitals fight a drug-resistant bug that can kill. Chicago Daily Herald; 19th January 2009. Available from: http://www.dailyherald.com/story/?id=265009&src=120. [accessed 12.02.09].
22. Stirling B., Littlejohn P., and Willbond M.L. Nurses and the control of infectious disease: understanding epidemiology and disease transmission is vital to nursing care. Can Nurse 100 9 (2004) 16-20
23. Bartlett J.G., Onderdonk A.B., Cisneros R.L., et al. Clindamycin-associated colitis due to a toxin-producing species of Clostridium in hamsters. J Infect Dis 136 5 (1977) 701-705
24. Taylor N.S., Thorne G.M., and Bartlett J.G. Comparison of two toxins produced by Clostridium difficile. Infect Immun 34 3 (1981) 1036-1043
25. Miller M.A. Clinical management of Clostridium difficile-associated disease. Clin Infect Dis 45 Suppl. 2 (2007) S122-S128
26. Ricciardi R., Rothenberger D.A., Madoff R.D., and Baxter N.N. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142 7 (2007) 624-631
27. McDonald L.C., Killgore G.E., Thompson A., et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 353 23 (2005) 2433-2441
28. Eggertson L. Clostridium difficile may have killed 2000 in Quebec: study. CMAJ 173 9 (2005) 1020-1021
29. Johnson S., Gerding D.N., Olson M.M., et al. Prospective, controlled study of vinyl glove use to interrupt Clostridium difficile nosocomial transmission. Am J Med 88 2 (1990) 137-140
30. Karpa K.D. Probiotics for Clostridium difficile diarrhea: putting it into perspective. Ann Pharmacother 41 7 (2007) 1284-1287
31. Gorbach S.L. Probiotics and gastrointestinal health. Am J Gastroenterol 95 Suppl. 1 (2000) S2-S3
32. Seal D., Borriello S.P., Barclay F., Welch A., Piper M., and Bonnycastle M. Treatment of relapsing Clostridium difficile diarrhea by administration of a non-toxigenic strain. Eur J Clin Microbiol 6 1 (1987) 51-53
33. Iizuka M., Konno S., Itou H., et al. Novel evidence suggesting Clostridium difficile is present in human gut microbiota more frequently than previously suspected. Microbiol Immunol 48 11 (2004) 889-892
34. Noren T., Akerlund E., Back E., et al. Molecular epidemiology of hospital-associated and community-acquired Clostridium difficile infection in a Swedish county. J Clin Microbiol 42 8 (2004) 3635-3643
35. Thomas M.R., Litin S.C., Osmon D.R., Corr A.P., Weaver A.L., and Lohse C.M. Lack of effect of Lactobacillus GG on antibiotic-associated diarrhea: a randomized, placebo-controlled trial. Mayo Clin Proc 76 9 (2001) 883-889
36. Arvola T., Laiho K., Torkkeli S., et al. Prophylactic Lactobacillus GG reduces antibiotic-associated diarrhea in children with respiratory infections: a randomized study. Pediatrics 104 5 (1999) e64
37. Plummer S., Weaver M.A., Harris J.C., Dee P., and Hunter J. Clostridium difficile pilot study: effects of probiotic supplementation on the incidence of C. difficile diarrhoea. Int Microbiol 7 1 (2004) 59-62
38. Hickson M., Souza A.L., Muthu N., et al. Use of probiotic Lactobacillus preparation to prevent diarrhea associated with antibiotics: randomized double blind placebo controlled trial. BMJ 335 7610 (2007) 80 [epub ahead of print, accessed 11.07.07]
39. Wilcox M.H., and Sandoe J.A. Probiotics and diarrhoea: data are not widely applicable. BMJ 335 7612 (2007) 171
40. Billyard T. Probiotics and diarrhea: no high risk antibiotics?. BMJ 335 7612 (2007) 171
41. Miller M. Commentary. Evid Based Med 13 (2008) 2-46
42. Graul T. Reduction of Clostridium difficile in acute care: Lactobacillus acidophilus and bifidobacterium as FLORAjen3 protocol (2001), American Association of Nurse Practitioners
43. Juntunen M., Kirjavainen P.V., Ouwehand A.C., Salminen S.J., and Isolarui E. Adherence of probiotic bacteria to human intestinal mucus in healthy infants and during rotavirus infection. Clin Diagn Lab Immunol 8 2 (2001) 293-296
44. McFarland L.V., Surawicz C.M., Greenberg R.N., et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90 3 (1995) 439-448
45. Chang J.Y., Antonopoulos D.A., Kalra A., et al. Decreased diversity of the fecal Microbiome in recurrent Clostridium difficile-associated diarrhea. J Infect Dis 197 3 (2008) 435-438
46. Austin N. Spores, babies, and alcohol. A nurse's battle with C. difficile. RN 2007;70(3):39-43.